Biopharmaceutical venture fund and managed care organization experts believe FDA should stay out of the medical product pricing and value arenas and instead let the marketplace determine value. FDA put out a guidance document last year clarifying the type of health care economic information (HCEI) that drug makers can send to payers, and the agency has increasingly engaged in discussions on the issue. But, up to now, FDA has largely put the burden of showing value on industry, the experts...